On Thursday, December 11, 2025, the Food and Drug Administration (FDA) announced a proposal to approve a new sunscreen ingredient called bemotrizinol. This ingredient has been used in Europe, Australia, and several Asian countries for many years. Experts assert that bemotrizinol offers better protection against harmful ultraviolet A (UVA) and B (UVB) rays compared to the current options permitted in the United States. Sunscreens in the US have often been confined to a limited number of approved ingredients, prompting criticism about the slow approval processes compared to other regions. The FDA's proposal allows the use of bemotrizinol in concentrations of up to 6%. This move marks the first introduction of a new UV filter in the US in over 25 years. Currently, sunscreen ingredients in the US are classified as over-the-counter drugs, requiring extensive clinical trials for safety and effectiveness before approval. In contrast, many other countries treat sunscreens as cosmetics, which streamlines their approval process significantly. FDA officials, including Commissioner Marty Makary, acknowledged that the agency has historically been slow in this area, resulting in fewer options for American consumers. Experts have pointed out that while mineral sunscreens, which use zinc oxide or titanium dioxide, can provide broad-spectrum protection, they often leave a white residue on the skin. In comparison, chemical sunscreens can be favored by consumers for their cosmetic feel, but they may not block UV rays effectively without a combination of different filters. Notably, bemotrizinol stands out as it does not penetrate the skin or enter the bloodstream, contributing to a favorable safety profile. Dermatologists have noted that many current chemical UV filters can cause skin irritation, especially for individuals with sensitive skin conditions such as acne or eczema, making bemotrizinol a more tolerable alternative. As the FDA moves forward with this proposal, it signals a recognition of the importance of adapting sunscreen regulations to keep pace with innovations in product formulation and safety research. The ultimate goal is to provide consumers with effective sun protection while considering public health perspectives, as skin cancer remains the most common cancer in America. Therefore, the inclusion of this new ingredient could offer a much-needed expansion of sun protection options in the U.S. market.

The differences in sunscreen regulations between the FDA and European authorities reflect varying approaches to consumer safety and public health. In the United States, the FDA has established specific guidelines for sunscreens, categorizing them as over-the-counter (OTC) drugs. This classification requires manufacturers to conduct extensive safety and efficacy testing. However, the FDA has been criticized for its slow approval process and for not recognizing many of the advanced sunscreen ingredients that are widely used in Europe. For instance, Europeans enjoy access to innovative chemical filters that provide enhanced UV protection, yet these are often unapproved by the FDA due to stringent regulatory measures. Contrarily, European regulations regarding sunscreens, governed by the European Commission, allow for a broader range of UV filters, enabling manufacturers to formulate products with improved effectiveness and safety profiles. The EU also employs a more proactive stance on updating its regulations, allowing for quicker incorporation of new research and data on sunscreen ingredients. Many of the ingredients banned or restricted by the FDA, such as certain preservatives and UV filters like Oxybenzone, are used in Europe, where they have undergone rigorous safety assessments. Consumer awareness and safety perceptions also differ between the two regions. European consumers generally have access to a wider array of sunscreen products, as the market is more diverse due to fewer restrictions. This offers consumers better choices tailored to their skin types and sun exposure habits. Additionally, there is a growing emphasis in Europe on the environmental impact of sunscreen ingredients, prompting regulatory bodies to evaluate the ecological effects of certain chemicals, leading to bans on ingredients harmful to marine life, such as oxybenzone and octinoxate in some jurisdictions. In conclusion, the ongoing debate surrounding sunscreen regulations highlights the complexities of balancing consumer safety with innovation in skincare. While the FDA's stringent processes aim to protect public health, they may inadvertently limit the availability of more effective products currently available in Europe. As consumer demand for safer and more effective sunscreens grows, this discrepancy presents a critical opportunity for dialogue and potential reform in both regulatory environments to enhance public health outcomes and environmental protections.